SeaSpine (SPNE) Getting Somewhat Favorable News Coverage, Analysis Shows
Media headlines about SeaSpine (NASDAQ:SPNE) have trended somewhat positive recently, Accern reports. The research firm identifies negative and positive media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. SeaSpine earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned news coverage about the medical equipment provider an impact score of 44.961858855075 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:
- SeaSpine Holdings (SPNE) Announces FDA 510(k) Clearance of OsteoBallast DBM in Resorbable Mesh (streetinsider.com)
- SeaSpine Announces FDA 510(k) Clearance of OsteoBallast™ Demineralized Bone Matrix in Resorbable Mesh (finance.yahoo.com)
- ETFs with exposure to SeaSpine Holdings Corp. : November 29, 2017 (finance.yahoo.com)
- Brokerages Set $18.00 Target Price for SeaSpine Holdings Corporation (SPNE) (americanbankingnews.com)
SPNE has been the subject of a number of research analyst reports. Zacks Investment Research raised shares of SeaSpine from a “hold” rating to a “buy” rating and set a $13.00 price objective for the company in a research report on Tuesday, September 12th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of SeaSpine in a research report on Friday, November 3rd. Piper Jaffray Companies reissued a “buy” rating and issued a $22.00 price target on shares of SeaSpine in a research report on Sunday, August 20th. Finally, BTIG Research reissued a “buy” rating on shares of SeaSpine in a research report on Monday, November 6th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. SeaSpine presently has an average rating of “Buy” and a consensus price target of $16.33.
SeaSpine (SPNE) opened at $10.05 on Tuesday. SeaSpine has a 1 year low of $6.31 and a 1 year high of $13.46.
SeaSpine Holdings Corporation is a medical technology company. The Company is focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. The Company operates through the development, manufacture and marketing of orthobiologics and spinal fusion hardware segment.
Receive News & Ratings for SeaSpine Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SeaSpine Holdings Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.